Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The medical device manufacturer won approval for a neurological product. Its latest Percept neurostimulator has been greenlighted by the U.S. FDA.

Why Medtronic Stock Got Off to a Roaring Start This Week

Rechargeable neurostimulator joins the Medtronic Percept ™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. DUBLIN , Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.

FDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology

Abbott Labs

DexCom

In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.

Wearable Technology Market Gains Ground, 3 Stocks in Focus

With CE Mark approval, the benefits of the MiniMed™ 780G system are now available with a new sensor that takes less than 10 seconds to insert1 DUBLIN , Jan. 8, 2024 /PRNewswire/ -- Medtronic plc  (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Stryker

NVIDIA

Stocks like Medtronic (MDT), Stryker (SYK) and NVIDIA (NVDA) are likely to benefit from the rising prospects of Generative AI in healthcare.

Generative AI Reshapes Healthcare: 3 Stocks in Limelight

New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN , Jan. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received CE (Conformité Européenne) Mark for its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniature, leadless pacemakers. Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.2 With approximately 40% more battery life compared to previous generations,1 Medtronic projects the battery life of Micra AV2 and Micra VR2 is nearly 16 and 17 years, respectively.3 This means more than 80% of patients who receive a Micra may only require one device for life.3 This CE Mark milestone follows U.S. Food and Drug Administration approval for the Micra AV2 and VR2 devices in 2023.

Medtronic receives CE Mark for its next generation Micra leadless pacing systems

Conagra Brands

At this point, investors are back to looking for inflation-proof stocks to shield their portfolios. After closing 2023 on a bullish note, as an early Santa Claus rally sent markets back to all-time highs, we're entering 2024 on a muted note.

Inflation and Interest Rates: 3 Stocks Set to Thrive in a Changing Economic Climate

BellRing Brands Inc

Hershey

WK Kellogg Co

Mondelez

Insulet

Post Holdings

J. M. Smucker

Utz Brands

Zimmer Biomet Hlds

Investors have such high hopes for popular weight-loss medications like Wegovy and Ozempic, the wonder drugs have sent shock waves through the stock market.

Ozempic and other weight-loss drugs' popularity set these stocks up for big gains

Amazon

Booking Hlds

UiPath

Quipt Home Medical Corp

Raytheon Technologies

The market is flying as we enter 2024, but some sectors offer compelling values. Other stocks will be terrific buys when they return to Earth.

6 Top Long-Term Stocks On My 2024 Wishlist

The medical device maker's payout ratio is alarmingly high at close to 90% of earnings. Plus, its quarterly free cash flow recently fell well short of what it pays out in dividends.

Is Medtronic's High-Yielding Dividend in Danger?

Enphase Energy

Alphabet

Artificial intelligence (AI) holds promise for many industries, sparking public imagination about the capabilities it may one day attain. However, we must temper expectations when it comes to AI predictions for the stock market.

AI Predictions: Meta's Llama Says These Will Be the 3 Best-Performing Stocks in 2024

H&R Block

Nintendo

Finding deep value stocks involves pinning down and investing in significantly undervalued companies based on their material worth. In effect, to find deep value stocks, you do research to find something – anything – the market missed and capitalized on the mispricing.

3 Deep Value Stocks for Hidden Gems in 2024

Cincinnati Financial

Hormel Foods

Leggett & Platt

McCormick

NextEra Energy

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

T. Rowe Price Group

Walgreens

Exxon Mobil

The ProShares S&P 500 Dividend Aristocrats ETF continues its recent good run in December, through the 22nd, the ETF is up 3.91%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

My Best Dividend Aristocrats For January 2024

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Up 2.9% Since Last Earnings Report: Can It Continue?

GE HealthCare Technologies Inc

Hologic

Investors looking to tap the budding prospects in the lucrative AI market in 2024 can count on Medtronic (MDT), GE HealthCare Technologies (GEHC) and Hologic (HOLX).

3 MedTech Stocks With Potential to Benefit From AI Boom in 2024

Tenet Healthcare

As the Baby Boomers age, the number of elderly Americans has risen quickly. Specifically, the number of those 65 and older in the U.S. jumped 38.6% between 2010 and 2020 to 55.8 million.

3 Aging Population Stocks to Profit from the Boomer Generation

DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 42nd annual J.P. Morgan healthcare conference on Monday, January 8, 2024.

Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

Caterpillar

Emerson Electric

General Motors

Verizon

Walmart

Dividend stocks are about to enjoy a renaissance. Just look what happened with Costco (NASDAQ: COST ) last week – the warehouse giant announced a special $15 cash dividend and shares soared to new all-time highs.

7 Undervalued Dividend Stocks to Buy for a Bargain

In a recent disclosure, United States Representative for Michigan's 6th congressional district Debbie Dingell has come under scrutiny for her stock purchase in Medtronic (NYSE: MDT), a prominent medical devices company.

US Politician makes suspicious health stock purchase

The medical-device giant won approval for a device that combats irregular heartbeats. The FDA gave the green light to the PulseSelect PFA System.

Why Medtronic Stock Topped the Market on Thursday

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Federal Realty Investment Trust

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 66 Aristocrats, screened as of December 12, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 13.71%-31.37% topped-by XOM & CVX. By yield, WBA topped-all Aristocrats. Top-ten Yields from ABBV, ESS, CVX, FRT, BEN, TROW, AMCR, O, MMM, & WBA, averaged 5.13%.

5 Dividend Aristocrats Signal Buy In December, With 6 To Watch

News for Medtronic Stock (MDT)